Evidence map›Paper›PMID 36607486›Full record

ArticleBreast cancer research and treatment2023

Disparities in the use of assisted reproductive technologies after breast cancer: a population-based study.

Clare Meernik, Kirsten Jorgensen, Chi-Fang Wu, Caitlin C Murphy, Valerie L Baker, Paula C Brady, Roni Nitecki, Hazel B Nichols, J Alejandro Rauh-Hain

Open access · greenAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Gynecologic Care of Black Breast Cancer Survivors.Current breast cancer reports · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Clare MeernikDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.ORCID http://orcid.org/0000-0002-8564-1266
Kirsten JorgensenDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chi-Fang WuDepartment of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Caitlin C MurphyDepartment of Health Promotion and Behavioral Sciences, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.
Valerie L BakerDivision of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Paula C BradyColumbia University Fertility Center, Columbia University Irving Medical Center, New York, NY, USA.
Roni NiteckiDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hazel B NicholsDepartment of Epidemiology, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, NC, USA.
J Alejandro Rauh-HainDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jarauh@mdanderson.org.ORCID http://orcid.org/0000-0001-9985-5954
The University of Texas MD Anderson Cancer Center · USColumbia University Irving Medical Center · USDuke University · USJohns Hopkins University · USThe University of Texas Health Science Center at Houston · USUniversity of North Carolina at Chapel Hill · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Training of Academic Gynecologic OncologistsT32CA101642 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIL K SOOD, Kathleen Schmeler · 2005 to 2026
$9.2M
Cancer Control Education ProgramT32CA057726 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Melissa B Gilkey, Melissa A. Troester · 2017 to 2026
$3.7M
Obstetrical and Oncological Outcomes Among Reproductive Age Women with Gynecological and Breast CancerK08CA234333 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI RAUH-HAIN, JOSE ALEJANDRO · 2018 to 2022
$1.2M
Assisted Reproductive Technology Use After Adolescent and Young Adult Cancer in North CarolinaF31CA260787 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MEERNIK, CLARE E · 2021 to 2021
$36k
NCI NIH HHS F31 CA260787NCI NIH HHS K08 CA234333NCI NIH HHS P30 CA016672NCI NIH HHS T32 CA057726NCI NIH HHS T32 CA101642
6 · The paper itself

Abstract

purposeEquitable access to oncofertility services is a key component of cancer survivorship care, but factors affecting access and use remain understudied.

methodsTo describe disparities in assisted reproductive technology (ART) use among women with breast cancer in California, we conducted a population-based cohort study using linked oncology, ART, and demographic data. We identified women age 18-45 years diagnosed with invasive breast cancer between 2000 and 2015. The primary outcome was ART use-including oocyte/embryo cryopreservation or embryo transfer-after cancer diagnosis. We used log-binomial regression to estimate prevalence ratios (PRs) and 95% confidence intervals (CIs) to identify factors associated with ART use.

resultsAmong 36,468 women with invasive breast cancer, 206 (0.56%) used ART. Women significantly less likely to use ART were age 36-45 years at diagnosis (vs. 18-35 years: PR = 0.17, 95% CI 0.13-0.22); non-Hispanic Black or Hispanic (vs. non-Hispanic White: PR = 0.31, 95% CI 0.21-0.46); had at least one child (vs. no children: adjusted PR [aPR] = 0.39, 95% CI 0.25-0.60); or lived in non-urban areas (vs. urban: aPR = 0.28, 95% CI 0.10-0.75), whereas women more likely to use ART lived in high-SES areas (vs. low-/middle-SES areas: aPR = 2.93, 95% CI 2.04-4.20) or had private insurance (vs. public/other insurance: aPR = 2.95, 95% CI 1.59-5.49).

conclusionWomen with breast cancer who are socially or economically disadvantaged, or who already had a child, are substantially less likely to use ART after diagnosis. The implementation of policies or programs targeting more equitable access to fertility services for women with cancer is warranted.

Indexed as

Breast NeoplasmsCohort StudiesEthnicityFemaleHumansPregnancyPregnancy OutcomeReproductive Techniques, AssistedAssisted reproductive technologyBreast cancerDisparitiesFertility preservation

Identifiers

PMID36607486
PMCPMC10184512
OpenAlexW4313575691

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.